Top Wall Street analysts have issued Buy ratings and price targets for two promising biotech companies, TriSalus Life Sciences (TLSI) and GeoVax Labs (GOVX). Analyst Jason Wittes of Roth MKM initiated coverage on TriSalus with a Buy rating and a $11 price target, while James Molloy of Alliance Global Partners gave GeoVax Labs a Buy rating and a $15 price target. These optimistic assessments could signal exciting times ahead for both companies.
US stocks closed higher on Wednesday, driven by anticipation for Federal Reserve Chair Jerome Powell’s speech at Jackson Hole on Friday. The S&P 500, Nasdaq, and Dow Jones all gained, with Snowflake, GeoVax Labs, Zoom, Target, and Tesla among the top performers.
GeoVax Labs Inc. (GOVX) stock saw a significant rise following the confirmation of a new mpox case in Wayne County, Michigan. This news comes amid a global health emergency declared by the WHO due to a surge in mpox cases, particularly in Africa. GeoVax, a biotech company specializing in immunotherapies and vaccines, has previously shown promising results with its vaccines in preventing mpox.
GeoVax Labs Inc (GOVX) shares have surged over 225% in the past week, driven by heightened investor interest in mpox (monkeypox) related stocks. This surge follows the World Health Organization’s declaration of a public health emergency due to the mpox outbreak in Africa. GeoVax, a clinical-stage biotechnology company developing vaccines against infectious diseases, has previously published research suggesting its vaccines could help prevent mpox.
